MedTrace Logo

Raltegravir and Atazanavir Replacing Current Suppressive Treatment Because of Side Effects in Current Treatment

NCT00751153 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2008-10-09

No results posted yet for this study

Summary

Subjects with HIV who have viral suppression on current regimen but also have side effects/intolerance will change their current regimen to a combination of Raltegravir and Atazanavir and be monitored for viral and immunological response and quality of life.

Conditions

  • HIV Infections

Interventions

DRUG

Raltegravir and Atazanavir

Rategravir 400 BID, Atazanavir 400 mg daily

Sponsors & Collaborators

  • Peter J. Ruane, M.D., Inc.

    lead OTHER

Principal Investigators

  • Peter J Ruane, MB · Peter J Ruane MD Inc

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2009-10-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00751153 on ClinicalTrials.gov